AAMDSIF is pleased to announce that we will host a support group exclusively for Health Care Professionals diagnosed with aplastic anemia aplastic anemia: (ay-PLASS-tik uh-NEE_
Relapse remains the main cause of death following allogeneic hematopoietic cell transplantation (HCT) for patients with high-risk myeloid malignancies. Post-transplant maintenance therapy may reduce relapse risk and improve outcomes. We previously showed that post-transplant azacitidine
Baseline IPSS-M risk, response to hypomethylating agent (HMA) therapy, and receipt of allogeneic stem cell transplant
The World Health Organization and international consensus 2022 classifications have proposed lowering the absolute monocyte monocyte:
Approximately half of patients with myelodysplastic syndromes myelodysplastic syndromes:
Relapse after allogeneic hematopoietic cell transplantation (alloHCT) remains a challenge for patients with acute myeloid leukemia
Saturday, October 24, 2026
Conference Co-Chairs
Uma Borate, MBBS
Alice Mims, MD
Dr. Chen is currently with the Rutgers Cancer Institute, the only NCI-designated cancer center in the state, where cutting-edge cancer research is conducted and state-of-the-art cancer care is delivered. Her interest in hematological malignancies started in medical school, driving her to pursue research in this field. After graduating from West China Medical School, she joined the University of Cincinnati’s Cancer and Cell Biology program, where her primary research focused on targeting autophagy in acute leukemia and earned my PhD. Following this, she completed her internal medicine residency
